Neurophth
PrivateLast Round
Series D
Aug 25, 2026
Est. Valuation
$700M
Total Funding Raised
$240.67M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neurophth is a biotechnology company that develops gene therapies for the treatment of ophthalmological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurophth Comparables
Compare Neurophth with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SparingVision | 84% | |
| HuidaGene Therapeutics | 84% | |
| Beacon Therapeutics | 83% | |
Neurophth Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 25, 2026 | ||||
| Series C Extension | Aug 11, 2023 | ||||
| Series C | Nov 23, 2021 | ||||
| Series B | Feb 9, 2021 | ||||
| Series A | Apr 9, 2020 | ||||
Angel | Aug 1, 2018 |
Key People
Founding team and executive leadership
Neurophth Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Huaxin Investment China InnoVision Capital | Series B |
| Oriza Holdings | Series B |
| 招银国际金融有限公司 | Series C |
| Northern Light Venture Capital | Angel, Series B, Series A |
| InnoVision Capital | Series B |
| InnoStar Capital | Series A |
| Shanghai International Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 25, 2026
Completed a Series D funding round.
- Aug 11, 2023
$95M round led by Guangzhou Financial Holdings Fund Management.
Neurophth Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurophth's valuation, stock price, and market status.